As of June this year, based on Medpace Holdings's latest financial report, the company's current EPS (TTM) is $16.22. Medpace Holdings's earnings per share in 2025 came in at $15.64, marking an increase from $13.06 in 2024. Medpace Holdings's EPS for the quarterly period ending on Mar 31, 2026 was $4.35.
The yearly EPS in 2025 was $15.64, an increase of 19.8% compared to $13.06 recorded in 2024. The quarterly EPS for the period ending Mar 31, 2026, was $4.35, marking a 15.4% increase compared to the same quarter last year. MEDP's TTM EPS is $16.22 as of March 2026. Medpace Holdings's EPS for 2024 was $13.06, a 42% rise from 2023.
Medpace Holdings has recorded a growth in earnings per share of 15.4% over the past 12 months (YoY, quarterly). For the last three years, MEDP had an average yearly EPS growth of 27.4%. Medpace Holdings had an average annual EPS growth of 30.9% over the last five years.
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| VIVS VivoSim Labs Inc. | 0.67 | 91.2% | N/A | N/A |
| ORMP Oramed Pharmaceuticals Inc | 1.45 | 418.8% | N/A | N/A |
| OMER Omeros Corp | 7.07 | 98.1% | N/A | N/A |
| MEDP Medpace Holdings Inc | 28.88 | 19.8% | 27.4% | 30.9% |
| OLMA Olema Pharmaceuticals Inc | N/A | 15% | N/A | N/A |
| ORIC Oric Pharmaceuticals Inc | N/A | 19.7% | N/A | N/A |
All data is based on quarterly TTM periods, unless otherwise specified.